Last 43 quarters of trend data · Healthcare · Drug Discovery Platforms
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -9.69 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 41.71 | 19.80 | 27.14 | 36.33 | 58.62 | 32.49 | 28.67 | 34.22 | 26.60 | 37.53 | 19.39 | 10.19 | 10.30 | 11.64 | 13.67 | 13.55 | 13.51 | 23.60 | 16.28 | 14.46 | 36.00 |
| — | -39.1% | -5.4% | +6.2% | +120.4% | -13.4% | +47.8% | +235.7% | +158.3% | +222.3% | +41.8% | -24.8% | -23.8% | -50.7% | -16.0% | -6.3% | -62.5% | — | — | — | — | |
| P/B Ratio | 9.67 | 6.50 | 7.85 | 8.72 | 10.75 | 9.52 | 15.00 | 13.68 | 6.12 | 5.34 | 2.37 | 3.32 | 3.09 | 4.43 | 3.38 | 3.33 | 3.43 | 4.14 | 2.81 | 2.40 | 2.85 |
| — | -31.7% | -47.6% | -36.3% | +75.7% | +78.5% | +532.5% | +311.6% | +98.3% | +20.3% | -29.8% | -0.4% | -10.1% | +7.1% | +20.3% | +39.0% | +20.6% | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 27.8% | 41.6% | 45.4% | 22.2% | 19.8% | 25.2% | 37.8% | 42.8% | 27.8% | 20.5% | 37.7% | 32.4% | 37.1% | 45.7% | 46.6% | 24.5% | 43.5% | 33.3% | 41.9% | 21.0% | 38.6% |
| — | +64.9% | +20.3% | -48.1% | -28.8% | +22.9% | +0.0% | +31.8% | -25.1% | -55.1% | -19.0% | +32.3% | -14.6% | +37.3% | +11.1% | +16.7% | +12.6% | +163.7% | -31.3% | -60.8% | -7.2% | |
| Operating Margin | -408.4% | -203.6% | -289.4% | -254.8% | -1121.3% | -321.8% | -211.8% | -305.7% | -221.0% | -318.4% | -462.5% | -249.0% | -402.8% | -125.7% | -213.4% | -319.1% | -173.4% | -226.7% | -143.5% | -767.5% | -543.5% |
| — | +36.7% | -36.7% | +16.7% | -407.4% | -1.1% | +54.2% | -22.8% | +45.1% | -153.4% | -116.7% | +22.0% | -132.3% | +44.6% | -48.7% | +58.4% | +68.1% | -0.5% | -97.5% | -22.5% | -5100.4% | |
| Net Margin | -404.1% | -201.3% | -286.6% | -241.6% | -1119.0% | -321.4% | -208.1% | -858.7% | -211.1% | -385.0% | -464.6% | -358.5% | -411.4% | -126.4% | -212.9% | -318.3% | -174.7% | -228.7% | -145.2% | -766.1% | -555.3% |
| — | +37.4% | -37.7% | +71.9% | -430.2% | +16.5% | +55.2% | -139.5% | +48.7% | -204.6% | -118.3% | -12.6% | -135.5% | +44.7% | -46.6% | +58.4% | +68.5% | +6.0% | -99.3% | -18.4% | -5011.2% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -125.6% | -15.6% | -19.6% | -13.6% | -48.3% | -29.4% | -24.1% | -62.5% | -11.5% | -13.2% | -19.2% | -31.0% | -27.9% | -11.4% | -12.5% | -18.3% | -10.7% | -9.7% | -6.1% | -28.8% | -14.5% |
| — | +47.1% | +18.6% | +78.2% | -319.6% | -122.8% | -25.6% | -101.7% | +58.8% | -16.3% | -53.8% | -68.8% | -160.5% | -16.9% | -105.9% | +36.3% | +26.2% | -41.5% | -43.2% | +8.2% | -1359.3% | |
| ROA | -109.6% | -13.4% | -17.2% | -12.1% | -41.6% | -24.5% | -20.4% | -55.1% | -10.4% | -11.8% | -16.7% | -23.5% | -19.1% | -8.9% | -11.2% | -16.7% | -9.8% | -8.9% | -5.6% | -26.8% | -12.3% |
| — | +45.5% | +15.6% | +78.0% | -299.9% | -106.8% | -21.8% | -135.0% | +45.6% | -32.5% | -49.5% | -40.5% | -95.5% | -0.2% | -99.4% | +37.6% | +20.3% | -77.9% | -82.0% | -18.8% | -1671.6% | |
| ROIC | -268.1% | -30.9% | -41.2% | -31.9% | -137.9% | -71.7% | -44.9% | -36.7% | -18.4% | -18.5% | -24.2% | -15.2% | -19.1% | -9.2% | -11.4% | -18.2% | -11.2% | -10.6% | -7.1% | -35.0% | -12.9% |
| — | +56.9% | +8.2% | +13.0% | -650.3% | -288.5% | -85.7% | -141.7% | +3.6% | -101.4% | -112.7% | +16.6% | -70.7% | +13.8% | -59.1% | +48.1% | +13.5% | -165.1% | -171.3% | -89.6% | -2075.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.04 | 0.04 | 0.04 | 0.04 | 0.03 | 0.03 | 0.06 | 0.03 | 0.02 | 0.02 | 0.04 | 0.04 | 0.40 | 0.33 | 0.03 | 0.02 | 0.02 | 0.02 | 0.02 | 0.01 | 0.02 |
| — | +14.7% | -29.8% | +26.8% | +60.6% | +85.1% | +40.1% | -22.7% | -95.5% | -94.8% | +36.5% | +72.9% | +1851.1% | +1466.6% | +34.2% | +91.0% | +30.8% | -91.5% | -90.5% | -95.5% | -94.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 6.36 | 4.21 | 5.26 | 6.36 | 7.53 | 4.78 | 3.71 | 4.88 | 4.96 | 6.57 | 6.16 | 1.02 | 2.79 | 3.74 | 2.54 | 3.60 | 4.44 | 5.12 | 6.42 | 7.01 | 5.92 |
| — | -12.0% | +41.8% | +30.4% | +51.7% | -27.1% | -39.8% | +376.9% | +78.1% | +75.3% | +142.4% | -71.6% | -37.3% | -26.8% | -60.4% | -48.7% | -25.0% | +2139.7% | +1632.9% | +5633.9% | +4579.0% | |
| Quick Ratio | 6.21 | 4.02 | 5.11 | 6.21 | 7.35 | 4.70 | 3.48 | 4.66 | 4.83 | 6.36 | 6.04 | 0.85 | 2.54 | 3.57 | 2.31 | 3.29 | 4.21 | 4.92 | 6.24 | 6.84 | 5.80 |
| — | -14.4% | +47.1% | +33.2% | +52.3% | -26.2% | -42.5% | +445.9% | +89.8% | +78.4% | +161.6% | -74.1% | -39.6% | -27.5% | -63.0% | -51.9% | -27.4% | +2344.0% | +1765.5% | +6627.3% | +5113.0% | |
| Interest Coverage | -364.19 | -182.73 | -246.99 | -180.49 | -696.98 | -345.50 | -235.20 | -1474.46 | -337.14 | -338.71 | -219.25 | -80.03 | -42.78 | -88.79 | -319.67 | — | -270.18 | -233.52 | -166.88 | -1194.19 | -46.09 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 43 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NTRB stock.
Nutriband Inc.'s current P/E is -9.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nutriband Inc.'s current operating margin is -408.4%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nutriband Inc.'s business trajectory between earnings reports.